Abstract

The skin secretions of Neotropical phyllomedusine leaf frogs have proven to be a rich source of biologically active peptides, including antimicrobials. The major families of antimicrobial peptides (AMPs) reported are the dermaseptins and phylloseptins and the minor families are the dermatoxins, phylloxins, plasticins, distinctins, and medusins. Here, we report a novel AMP of 10 amino acid residues (LRPAILVRIKamide), named balteatide, from the skin secretion of wild Peruvian purple-sided leaf frogs, Phyllomedusa baltea. Balteatide was found to exhibit a 90% sequence identity with sauvatide, a potent myotropic peptide from the skin secretion of Phyllomedusa sauvagei. However, despite both peptides exhibiting only a single amino acid difference (I/T at position 9), sauvatide is devoid of antimicrobial activity and balteatide is devoid of myotropic activity. Balteatide was found to have differential activity against the Gram-positive bacterium, Staphylococcus aureus; the Gram-negative bacterium, Escherichia coli; and the yeast, Candida albicans, and unusual for phyllomedusine frog skin AMPs, was most potent (MIC 32 mg/L) against the yeast. Balteatide was also devoid of haemolytic activity up to concentrations of 512 mg/L. Phyllomedusine frog skin secretions thus continue to provide novel AMPs, some of which may provide templates for the rational design of new classes of anti-infective therapeutics.

Highlights

  • The development of novel classes of anti-infective therapeutics has become an imperative within the pharmaceutical industry as pathogens continue to become resistant to all currently available antibiotics on a global scale [1,2,3]

  • The spread of microbial resistance is leading to a pandemic in untreatable or difficult-to-treat infections of both humans and livestock [1,2,3, 16]

  • Our increasing knowledge and database of naturally occurring antimicrobial peptides, whose origins in the biosphere are undoubtedly ancient, provide one possible avenue to pursue towards the goal of discovering or developing novel anti-infection therapeutics [2, 3, 18]

Read more

Summary

Introduction

The development of novel classes of anti-infective therapeutics has become an imperative within the pharmaceutical industry as pathogens continue to become resistant to all currently available antibiotics on a global scale [1,2,3]. Generally shunned by the industry as drug candidates, have attracted much research attention as current evidence suggests that they are of ancient origin and occur as a component of front-line defence against microbial infection within the innate immune systems of both invertebrates and vertebrates and they even occur in plant tissues [2, 3]. More than 500 different antimicrobial peptides (AMPs) have been reported from diverse natural sources and the majority of those present in contemporary online databases are of amphibian skin origin [4]. There are major obstacles to the use of AMPs systemically, they appear to be effective for topical use as they have been shown to be capable of

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call